Oksana Bohn1, Min Xi2, Natalie K Woodruff2, Gary L Hansen2,3, Charlene E McEvoy2,3. 1. University of Minnesota, Minneapolis, Minnesota, United States. 2. HealthPartners Institute, Bloomington, Minnesota, United States. 3. RespirTech, a Philips company, St. Paul, Minnesota, United States.
Abstract
PURPOSE: To assess whether the presence or absence of bronchiectasis has an impact on the patient-reported symptoms of chronic obstructive pulmonary disease (COPD) patients. METHODS: The study included participants from the COPD Genetic Epidemiology Study (COPDGene®) cohort with available high-resolution chest tomography reporting the presence or absence of bronchiectasis (BE+/BE-) and survey data reporting the presence or absence of chronic bronchitis symptoms (CB+/CB-). Patient symptoms based on the St George's Respiratory Questionnaire (SGRQ) were then compared for the different groups. RESULTS: The study population included 7976 participants, mean age 60, Global initiative for chronic Obstructive Lung Disease (GOLD) stages 0 to 4, 18.8% BE+, and 19.5% CB+. The presence or absence of radiographic bronchiectasis was not associated with higher frequency of chronic bronchitis (GOLD 0 group odds ratio [OR] 1.01 [0.78,1.31], GOLD 1-2 group OR 1.19 [0.95, 1.50], GOLD 3-4 group OR 1.26 [0.99, 1.60]). Similarly, CB+ participants had higher SGRQ scores than CB- participants regardless of the presence of BE. CONCLUSIONS: Across all GOLD stages, chronic bronchitis symptoms are associated with worse pulmonary symptoms and significant impairment in quality of life. For patients with chronic bronchitis, the presence or absence of bronchiectasis is not associated with a significant difference in SGRQ symptom scores. Symptoms of chronic bronchitis impose a heavy burden on patients and should be treated regardless of the presence or absence of underlying bronchiectasis. JCOPDF
PURPOSE: To assess whether the presence or absence of bronchiectasis has an impact on the patient-reported symptoms of chronic obstructive pulmonary disease (COPD) patients. METHODS: The study included participants from the COPD Genetic Epidemiology Study (COPDGene®) cohort with available high-resolution chest tomography reporting the presence or absence of bronchiectasis (BE+/BE-) and survey data reporting the presence or absence of chronic bronchitis symptoms (CB+/CB-). Patient symptoms based on the St George's Respiratory Questionnaire (SGRQ) were then compared for the different groups. RESULTS: The study population included 7976 participants, mean age 60, Global initiative for chronic Obstructive Lung Disease (GOLD) stages 0 to 4, 18.8% BE+, and 19.5% CB+. The presence or absence of radiographic bronchiectasis was not associated with higher frequency of chronic bronchitis (GOLD 0 group odds ratio [OR] 1.01 [0.78,1.31], GOLD 1-2 group OR 1.19 [0.95, 1.50], GOLD 3-4 group OR 1.26 [0.99, 1.60]). Similarly, CB+ participants had higher SGRQ scores than CB- participants regardless of the presence of BE. CONCLUSIONS: Across all GOLD stages, chronic bronchitis symptoms are associated with worse pulmonary symptoms and significant impairment in quality of life. For patients with chronic bronchitis, the presence or absence of bronchiectasis is not associated with a significant difference in SGRQ symptom scores. Symptoms of chronic bronchitis impose a heavy burden on patients and should be treated regardless of the presence or absence of underlying bronchiectasis. JCOPDF
Authors: Maria Montes de Oca; Ronald J Halbert; Maria Victorina Lopez; Rogelio Perez-Padilla; Carlos Tálamo; Dolores Moreno; Adrianna Muiño; José Roberto B Jardim; Gonzalo Valdivia; Julio Pertuzé; Ana Maria B Menezes Journal: Eur Respir J Date: 2012-01-26 Impact factor: 16.671
Authors: Diego J Maselli; Surya P Bhatt; Antonio Anzueto; Russell P Bowler; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Ashraf Fawzy; Marilyn G Foreman; Nicola A Hanania; Craig P Hersh; Victor Kim; Gregory L Kinney; Nirupama Putcha; Emily S Wan; J Michael Wells; Gloria E Westney; Kendra A Young; Edwin K Silverman; MeiLan K Han; Barry J Make Journal: Chest Date: 2019-05-30 Impact factor: 9.410
Authors: Eva Polverino; Katerina Dimakou; John Hurst; Miguel-Angel Martinez-Garcia; Marc Miravitlles; Pierluigi Paggiaro; Michal Shteinberg; Stefano Aliberti; James D Chalmers Journal: Eur Respir J Date: 2018-09-15 Impact factor: 16.671
Authors: Eva Polverino; Pieter C Goeminne; Melissa J McDonnell; Stefano Aliberti; Sara E Marshall; Michael R Loebinger; Marlene Murris; Rafael Cantón; Antoni Torres; Katerina Dimakou; Anthony De Soyza; Adam T Hill; Charles S Haworth; Montserrat Vendrell; Felix C Ringshausen; Dragan Subotic; Robert Wilson; Jordi Vilaró; Bjorn Stallberg; Tobias Welte; Gernot Rohde; Francesco Blasi; Stuart Elborn; Marta Almagro; Alan Timothy; Thomas Ruddy; Thomy Tonia; David Rigau; James D Chalmers Journal: Eur Respir J Date: 2017-09-09 Impact factor: 16.671